相关实验视频

Updated: Mar 4, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

DNA甲基化与·维勒布兰德因子和凝血因子VIII的血水平有关:社区动脉样硬化风险研究

Julie Hahn¹, Jan Bressler¹, Myriam Fornage^1,2

¹Human Genetics Center, Department of Epidemiology, School of Public Health, The University of Texas Health Science Center at Houston, Houston, USA.

Clinical epigenetics

|March 2, 2026

概括

这项研究揭示了与威尔布兰德因子 (VWF) 和因子VIII (FVIII) 水平相关的新型DNA甲基化位点,确定了NBEAL2和B3GALT4作为关键的表观遗传调节剂. 这些发现进一步提高了我们对VWF和FVIII监管的理解.

科学领域:

表观遗传学在表观遗传学中,表观遗传学是指表观遗传学.
基因组学就是基因组学.
心血管科学心血管科学

背景情况:

我们对CpG位点的DNA甲基化如何调节循环威尔布兰因子 (VWF) 和因子VIII (FVIII) 水平的理解有限.
VWF和FVIII在血液静止和血栓形成中至关重要,它们的失调与心血管疾病有关.

研究的目的:

调查白细胞DNA甲基化与VWF抗原和FVIII活性等离子体水平之间的关联.
确定调节VWF和FVIII的新型表观遗传位点.

主要方法:

在ARIC研究中的2597名黑人和1011名白人参与者进行了全表观基因组关联研究 (EWAS).
分析了483,735个CpG地点的VWF和FVIII水平的相关性.
在黑人参与者中发现分析,在白人参与者中复制.

主要成果:

在发现阶段确定了55个对VWF和46个对FVIII的显著CpG位点.
复制了VWF的13个CpG位点,映射到新的NBEAL2和已知的ABO位点.
复制了FVIII的12个CpG位点,映射到新的B3GALT4和已知的ABO/CORO1A位点.

结论:

在NBEAL2和B3GALT4位置确定了与VWF和FVIII水平的新型表观遗传关联.
NBEAL2对于血小板α颗粒生物合成至关重要,储存VWF.
B3GALT4参与VWF和FVIII的糖化,影响它们的功能.

更多相关视频

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies

Sample Preparation to Bioinformatics Analysis of DNA Methylation: Association Strategy for Obesity and Related Trait Studies

Published on: May 6, 2022

相关概念视频

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...